SLC5A2 and atrial fibrillation: SGLT2 inhibitor use was associated with a significantly lower risk of incident AF compared with DPP4 inhibitor use after inverse probability of treatment weighting (HR, 0.73; 95% CI, 0.57 to 0.91; p = 0.01; Supplementary Figure S1).